Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.42 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.42 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | FABP7 | O15540 | 1/20 | 0.40 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL42370 | 0.81 | EGFR (0.51) | TSHRHTR2AMAPTHDAC3HDAC4 | |
| SCHEMBL1568272 | 0.81 | TSHR (0.50) | TSHRHTR2AMAPTHDAC3HDAC4 | |
| SCHEMBL87863 | 0.79 | HSD17B10 (0.59) | TSHRHTR2AMAPTHDAC3HDAC4 | |
| SCHEMBL2108892 | 0.79 | TSHR (0.49) | TSHRHTR2AMAPTHDAC3HDAC4 | |
| SCHEMBL8279094 | 0.79 | POLB (0.50) | TSHRHTR2AMAPTHDAC3HDAC4 | |
| SCHEMBL14880206 | 0.76 | HDAC8 (0.53) | TSHRHTR2AMAPTHDAC3HDAC4 | |
| SCHEMBL23505970 | 0.75 | MAPT (0.47) | TSHRHTR2AMAPTHDAC3HDAC4 | |
| SCHEMBL8728938 | 0.75 | TSHR (0.45) | TSHRHTR2AMAPTHDAC3HDAC4 | |
| SCHEMBL8733809 | 0.75 | TSHR (0.45) | TSHRHTR2AMAPTHDAC3HDAC4 | |
| SCHEMBL409927 | 0.75 | ALDH1A1 (0.51) | TSHRHTR2AMAPTHDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220073446-A1 | Antigen Delivery Vectors and Constructs | ALTIMMUNE UK LIMITED (GB) | 2022-03-10 | — | — | US | disclosed |
| US-11066353-B2 | Antigen delivery vectors and constructs | ALTIMMUNE UK LTD (GB) | 2021-07-20 | — | — | US | disclosed |
| EP-2374477-B1 | Antigen delivery vectors and constructs | ALTIMMUNE UK LTD (GB) | 2016-09-07 | — | — | EP | disclosed |
| US-20150112042-A1 | Antigen Delivery Vectors and Constructs | ALTIMMUNE UK LIMITED (GB) | 2015-04-23 | — | — | US | disclosed |
| US-8759281-B2 | Antigen delivery vectors and constructs | IMMUNE TARGETING SYSTEMS LTD. (GB) | 2014-06-24 | — | — | US | disclosed |
| EP-1740207-B1 | ANTIGEN DELIVERY VECTORS AND CONSTRUCTS | IMMUNE TARGETING SYSTEMS ITS LTD (GB) | 2012-12-19 | — | — | EP | disclosed |
| US-20120315293-A1 | Antigen Delivery Vectors and Constructs | IMMUNE TARGETING SYSTEMS LTD. | 2012-12-13 | — | — | US | disclosed |
| US-8129333-B2 | Antigen delivery vectors and constructs | IMMUNE TARGETING SYSTEMS LTD. (GB) | 2012-03-06 | — | — | US | disclosed |
| US-20120034259-A1 | ANTIGEN DELIVERY VECTORS AND CONSTRUCTS | ALTIMMUNE UK LIMITED (GB) | 2012-02-09 | — | — | US | disclosed |
| US-8110540-B2 | Antigen delivery vectors and constructs | IMMUNE TARGETING SYSTEMS LTD. (GB) | 2012-02-07 | — | — | US | disclosed |
| US-8110541-B2 | Antigen delivery vectors and constructs | IMMUNE TARGETING SYSTEMS LTD. (GB) | 2012-02-07 | — | — | US | disclosed |
| EP-2374477-A1 | Antigen delivery vectors and constructs | Immune Targeting Systems (GB) | 2011-10-12 | — | — | EP | disclosed |
| US-20100183708-A1 | Antigen Delivery Vectors and Constructs | IMMUNE TARGETING SYSTEMS LTD. | 2010-07-22 | — | — | US | disclosed |
| US-20100183650-A1 | Antigen Delivery Vectors and Constructs | IMMUNE TARGETING SYSTEMS LTD. | 2010-07-22 | — | — | US | disclosed |
| US-7687455-B2 | comprising fluorocarbon vector-antigen, immunogens; vaccines, immunotherapy | IMMUNE TARGETING SYSTEMS LTD. (GB) | 2010-03-30 | — | — | US | disclosed |
| EP-1740207-A2 | ANTIGEN DELIVERY VECTORS AND CONSTRUCTS | Immune Targeting Systems (GB) | 2007-01-10 | — | — | EP | disclosed |
| US-20060013820-A1 | comprising fluorocarbon vector-antigen, immunogens; vaccines, immunotherapy | ALTIMMUNE UK LIMITED (GB) | 2006-01-19 | — | — | US | disclosed |
| WO-2005099752-A9 | ANTIGEN DELIVERY VECTORS AND CONSTRUCTS | IMMUNE TARGETING SYSTEMS (GB) | 2005-12-15 | — | — | WO | disclosed |
| WO-2005099752-A2 | ANTIGEN DELIVERY VECTORS AND CONSTRUCTS | IMMUNE TARGETING SYSTEMS (GB) | 2005-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100183650-A1 | Antigen Delivery Vectors and Constructs | LY96, CD74, CD69 | TSHR 3438/4885HTR2A 4872/4885MAPT 2475/4885 |
| US-20150112042-A1 | Antigen Delivery Vectors and Constructs | LY96, CD74, CD69 | TSHR 3438/4885HTR2A 4872/4885MAPT 2475/4885 |
| US-20120315293-A1 | Antigen Delivery Vectors and Constructs | LY96, CD74, CD69 | TSHR 3438/4885HTR2A 4872/4885MAPT 2475/4885 |
| US-20100183708-A1 | Antigen Delivery Vectors and Constructs | LY96, CD74, CD69 | TSHR 3438/4885HTR2A 4872/4885MAPT 2475/4885 |
| US-20220073446-A1 | Antigen Delivery Vectors and Constructs | LY96, CD74, CD69 | TSHR 3438/4885HTR2A 4872/4885MAPT 2475/4885 |
| US-20120034259-A1 | ANTIGEN DELIVERY VECTORS AND CONSTRUCTS | LY96, CD74, CD69 | TSHR 3438/4885HTR2A 4872/4885MAPT 2475/4885 |
| US-20060013820-A1 | comprising fluorocarbon vector-antigen, immunogens; vaccines, immunotherapy | LY96, CD74, HAVCR2 | TSHR 3789/4885HTR2A 4877/4885MAPT 1758/4885 |
| US-11066353-B2 | Antigen delivery vectors and constructs | LY96, CD74, CD69 | TSHR 3438/4885HTR2A 4872/4885MAPT 2475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.